The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors.

PubMed14 Apr 2026Cell metabolism● 6/10i

The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors.

Gonzalez-Rellan MJ, Riobello C, Fang S, Martins da Silva E, Koehler JA et al.

Semaglutide improved liver fibrosis, steatosis, and inflammation in mice with MASH through weight-loss-independent mechanisms targeting GLP-1 receptors on liver sinusoidal endothelial cells. Preclinical study using genetically modified mouse models with targeted GLP-1 receptor deletions and transcriptomic profiling. This identifies a novel hepatic mechanism for GLP-1 receptor agonists that could support liver indication development beyond weight loss effects. Study limited to mouse models without human validation.

Strategic Signal

This mechanistic data strengthens the scientific platform for GLP-1 receptor agonist development in NASH/MASH indications by demonstrating weight-independent hepatoprotective effects. Novo Nordisk's ongoing ESSENCE trial testing semaglutide in non-cirrhotic NASH gains additional mechanistic support for regulatory submissions. The endothelial cell mechanism could differentiate GLP-1 approaches from weight-loss-focused competitors in liver disease positioning with hepatologists and HTA bodies.

GLP-1Liver/NASHMechanismsNovo Nordisk

Original Abstract

Glucagon-like peptide-1 (GLP-1) medicines improve metabolic liver disease through weight-loss-dependent and -independent actions. Here, we interrogated semaglutide's action in mice with metabolic dysfunction-associated steatohepatitis (MASH). In Glp1rWnt1-/- mice resistant to GLP-1RA-induced weight loss, semaglutide improved steatosis, fibrosis, and immune remodeling. GEM-X Flex-seq localized Glp1r expression to pericentral liver sinusoidal endothelial cells (ECs) (LSECs) and CD8+ T cells. EC Glp1r deletion in Glp1rTie2-/- mice or AAV8-Cre-mediated hepatic EC Glp1r knockdown substantially abrogated semaglutide's hepatic benefits despite preserved weight loss. Transcriptomic profiling revealed that Glp1r+ LSECs adopt a stress-responsive phenotype in MASH that is reversed by semaglutide. Glp1r+ LSECs function as dominant contributors to semaglutide-regulated circuits linked to injury and repair involving VWF, SELE, CEACAM, and BMP. Molecular profiling revealed semaglutide-coordinated transcriptional and protein-level reversal of disease signatures. Together, the data using mouse models of MASH reveal an EC-specific, weight-loss-independent, semaglutide-regulated, GLP-1R-dependent intrahepatic network for improving liver health.

View original source ↗

Related signals

Strategic Signal

FDA1 Apr 2026New Drug Approval (NDA/BLA)High impact● 10/10i

FDA Approves Foundayo (Orforglipron) — New Drug Approval (NDA/BLA)

FDA approved orforglipron (Foundayo, Eli Lilly) for type 2 diabetes -- a once-daily oral small-molecule GLP-1 receptor agonist. Orforglipron is the first non-peptide oral GLP-1 approved in the US; oral semaglutide (Rybelsus, Novo Nordisk) has been approved for T2D since 2019 and expanded to obesity in January 2026. Unlike Rybelsus, orforglipron requires no fasting or water volume restrictions before dosing.

GLP-1Type 2 diabetesPricing/accessEli Lilly Novo Nordisk

Strategic Signal

Clinical Trial19 Mar 2026Phase 3High impact● 9/10i

Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)

Phase 3 SURMOUNT-1 tests once-weekly tirzepatide at three doses versus placebo in adults without type 2 diabetes who have obesity or are overweight with comorbidities. The randomized, double-blind trial targets 2,539 participants with primary efficacy assessment at 72 weeks. This represents tirzepatide's pivotal obesity trial against placebo, potentially supporting Eli Lilly's bid to compete directly with Wegovy in the non-diabetic obesity market. A prediabetes subgroup continues long-term to assess diabetes prevention.

Weight lossGLP-1Eli Lilly

Strategic Signal

Clinical Trial17 Apr 2026Phase 3High impact● 8/10i

A Phase 3, Open-Label Study of Once Daily LY3502970 Compared With Insulin Glargine in Adult Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Phase 3 open-label trial compared once-daily oral orforglipron versus insulin glargine in people with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study enrolled 2,749 participants with primary endpoint of time to first major adverse cardiovascular event, completed in March 2026. Eli Lilly is positioning orforglipron as a cardiovascular outcomes option in high-risk populations, directly competing with established insulin therapy in this indication. This represents the first cardiovascular outcomes trial for orforglipron following its April 2026 FDA approval for type 2 diabetes.

GLP-1Type 2 diabetesWeight lossCardiovascularEli Lilly

Strategic Signal

FDA1 Apr 2026FDA Press ReleaseHigh impact● 8/10i

FDA Approves First New Molecular Entity Under National Priority Voucher Program

FDA approved Foundayo (orforglipron) on April 1, 2026, marking the fifth approval under the Commissioner's National Priority Voucher pilot program. This represents approval of the first small-molecule oral GLP-1 receptor agonist, distinct from the peptide-based oral semaglutide (Rybelsus) approved by FDA in 2019. Eli Lilly gains competitive positioning in the oral GLP-1 space with a differentiated mechanism that requires no fasting restrictions. The approval leverages FDA's expedited voucher pathway designed to incentivize development of treatments addressing unmet medical needs.

GLP-1Type 2 diabetesEli Lilly